OBJECTIVE: To determine whether the number of hepatocytes containing AFP mRNA shed into the bloodstream during transarterial chemoembolization (TAE) affects the incidence and pattern of recurrence of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We developed a Taqman procedure to quantify AFP mRNA prospectively in 52 consecutive patients before and after TAE. Results are expressed in hepatocytes /mL. RESULTS: Thirteen of the patients (24.5%) were positive for AFP mRNA (42 +/- 19 hepatocytes/mL) before TAE and 13 (24.5%) (80 +/- 32 hepatocytes/mL) after TAE; the difference was not significant. The presence of AFP mRNA in the bloodstream before TAE was associated with larger nodules (85.2 +/- 73.8 mm versus 34.8 +/- 26.1 mm; P = 0.006). Six of the patients were excluded from the analysis because they underwent curative surgery or were lost to follow-up. The circulating levels of AFP mRNA released in the 46 remaining patients after TAE did not affect metastasis-free survival. A significant number of extrahepatic metastases were found in patients exhibiting at least 1 AFP mRNA-positive blood sample either before or after TAE. However, the TAE procedure did not increase the risk of extrahepatic recurrences. CONCLUSION: Cells containing AFP mRNA are inconsistently released into the circulation during TAE. The amount of these cells released does not affect the recurrence of HCC.
OBJECTIVE: To determine whether the number of hepatocytes containing AFP mRNA shed into the bloodstream during transarterial chemoembolization (TAE) affects the incidence and pattern of recurrence of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We developed a Taqman procedure to quantify AFP mRNA prospectively in 52 consecutive patients before and after TAE. Results are expressed in hepatocytes /mL. RESULTS: Thirteen of the patients (24.5%) were positive for AFP mRNA (42 +/- 19 hepatocytes/mL) before TAE and 13 (24.5%) (80 +/- 32 hepatocytes/mL) after TAE; the difference was not significant. The presence of AFP mRNA in the bloodstream before TAE was associated with larger nodules (85.2 +/- 73.8 mm versus 34.8 +/- 26.1 mm; P = 0.006). Six of the patients were excluded from the analysis because they underwent curative surgery or were lost to follow-up. The circulating levels of AFP mRNA released in the 46 remaining patients after TAE did not affect metastasis-free survival. A significant number of extrahepatic metastases were found in patients exhibiting at least 1 AFP mRNA-positive blood sample either before or after TAE. However, the TAE procedure did not increase the risk of extrahepatic recurrences. CONCLUSION: Cells containing AFP mRNA are inconsistently released into the circulation during TAE. The amount of these cells released does not affect the recurrence of HCC.
Authors: M Louha; J Nicolet; H Zylberberg; A Sabile; C Vons; G Vona; K Poussin; M Tournebize; F Capron; S Pol; D Franco; B Lacour; C Bréchot; P Paterlini-Bréchot Journal: Hepatology Date: 1999-03 Impact factor: 17.425
Authors: G Pelletier; A Roche; O Ink; M L Anciaux; S Derhy; P Rougier; C Lenoir; P Attali; J P Etienne Journal: J Hepatol Date: 1990-09 Impact factor: 25.083
Authors: M Monden; J Okamura; M Sakon; M Gotoh; K Kobayashi; K Umeshita; T Yamada; C Kuroda; M Sakurai; T Mori Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333
Authors: G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche Journal: J Hepatol Date: 1998-07 Impact factor: 25.083
Authors: L Pichard; I Fabre; G Fabre; J Domergue; B Saint Aubert; G Mourad; P Maurel Journal: Drug Metab Dispos Date: 1990 Sep-Oct Impact factor: 3.922
Authors: Siu Tim Cheung; Chi Leung Liu; Jeremy P H Chow; Yuk Ting Lee; Ying Chi Ip; Jenny C Y Ho; Sheung Tat Fan Journal: Neoplasia Date: 2006-09 Impact factor: 5.715
Authors: Sun-Young Kong; Joong-Won Park; Jin Oak Kim; Nam Oak Lee; Jung An Lee; Kyung Woo Park; Eun Kyung Hong; Chang-Min Kim Journal: J Cancer Res Clin Oncol Date: 2009-01-31 Impact factor: 4.553